10-K Filing

ACCELERATE DIAGNOSTICS, INC CIK: 727207 FY 2012

Filing Information

Form Type	10-K
Accession Number	`0001000096-12-000149`
Period End Date	20120731
Filing Date	20121026
Fiscal Year	2012
Fiscal Period	FY
XBRL Instance	axk-20120731.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 57 Income Statement 40 Cash Flow Statement 50 Stockholders Equity 17

Balance Sheet 57 line items

Line Item	Tag	Value	Unit	Period
Common Stock, no par value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common Stock, no par value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	19.00M	shares	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	45.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$283.27K	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	25.23M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$775.86K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$14.26M	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	11.10M	shares	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	11.10M	shares	Point-in-time
Trade accounts receivable	`ReceivablesNetCurrent`	$596.13K	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	25.23M	shares	Point-in-time
Trade accounts receivable	`ReceivablesNetCurrent`	$750.95K	USD	Point-in-time
Shares held for employee benefit	`DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital`	$1.13M	USD	Point-in-time
Inventory	`InventoryNet`	$10.26K	USD	Point-in-time
Inventory	`InventoryNet`	$30.28K	USD	Point-in-time
Shares held for employee benefit	`DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital`	$1.13M	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$17.93K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$20.58K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.42M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.04M	USD	Point-in-time
Long term accounts receivable, net of current portion	`LongTermInvestmentsAndReceivablesNet`	-	USD	Point-in-time
Long term accounts receivable, net of current portion	`LongTermInvestmentsAndReceivablesNet`	$745.44K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.53K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.96K	USD	Point-in-time
Investments, net	`Goodwill`	$1.30M	USD	Point-in-time
Investments, net	`Goodwill`	$1.49M	USD	Point-in-time
Intellectual property, net	`FiniteLivedIntangibleAssetsNet`	$680.94K	USD	Point-in-time
Intellectual property, net	`FiniteLivedIntangibleAssetsNet`	$2.79M	USD	Point-in-time
Total Assets	`Assets`	$6.26M	USD	Point-in-time
Total Assets	`Assets`	$17.21M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$34.96K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$63.03K	USD	Point-in-time
Accrued compensation and other liabilities	`EmployeeRelatedLiabilitiesCurrent`	$24.58K	USD	Point-in-time
Accrued compensation and other liabilities	`EmployeeRelatedLiabilitiesCurrent`	$1.24M	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$85.34K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$9.80K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$69.34K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.39M	USD	Point-in-time
Deferred compensation	`DeferredCompensationLiabilityCurrent`	$1.38M	USD	Point-in-time
Deferred compensation	`DeferredCompensationLiabilityCurrent`	$650.00K	USD	Point-in-time
Deferred compensation	`DeferredCompensationLiabilityCurrent`	$986.46K	USD	Point-in-time
Total liabilities	`Liabilities`	$1.45M	USD	Point-in-time
Total liabilities	`Liabilities`	$2.38M	USD	Point-in-time
Common stock, no par value; 45,000,000 shares authorized; 25,231,939 shares (2012);11,103,367 shares (2011) issued and outstanding	`CommonStockNoParValue`	$14.33M	USD	Point-in-time
Common stock, no par value; 45,000,000 shares authorized; 25,231,939 shares (2012);11,103,367 shares (2011) issued and outstanding	`CommonStockNoParValue`	$22.99M	USD	Point-in-time
Contributed capital	`AdditionalPaidInCapitalCommonStock`	$1.25M	USD	Point-in-time
Contributed capital	`AdditionalPaidInCapitalCommonStock`	$7.92M	USD	Point-in-time
Accumulated deficit	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-15.80M	USD	Point-in-time
Accumulated deficit	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-10.49M	USD	Point-in-time
Shares held for employee benefit (1,129,110 shares at cost)	`SharesHeldInEmployeeStockOptionPlanAllocated`	-273,600.00	shares	Point-in-time
Shares held for employee benefit (1,129,110 shares at cost)	`SharesHeldInEmployeeStockOptionPlanAllocated`	-273,600.00	shares	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$4.91M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$14.84M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$4.82M	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$17.21M	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$6.26M	USD	Point-in-time

Income Statement 40 line items

Line Item	Tag	Value	Unit	Period
Technical development fees	`ProfessionalAndContractServicesExpense`	$-842.41K	USD	Annual
Technical development fees	`ProfessionalAndContractServicesExpense`	$-140.00K	USD	Annual
OptiChem revenue	`LicensesRevenue`	$34.28K	USD	Annual
OptiChem revenue	`LicensesRevenue`	$45.91K	USD	Annual
License fees	`CostOfServicesLicensesAndServices`	-	USD	Annual
License fees	`CostOfServicesLicensesAndServices`	$-50.00K	USD	Annual
Qualified discovery therapeutic grant	`RevenueFromGrants`	$244.48K	USD	Annual
Qualified discovery therapeutic grant	`RevenueFromGrants`	-	USD	Annual
Total revenues	`SalesRevenueNet`	$235.91K	USD	Annual
Total revenues	`SalesRevenueNet`	$1.12M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$455.00K	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$431.91K	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$810.08K	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$2.95M	USD	Annual
Amortization	`AmortizationOfIntangibleAssets`	$253.50K	USD	Annual
Amortization	`AmortizationOfIntangibleAssets`	$203.46K	USD	Annual
Depreciation	`DepreciationDepletionAndAmortization`	$2.40K	USD	Annual
Depreciation	`DepreciationDepletionAndAmortization`	$2.10K	USD	Annual
Marketing and sales	`SellingAndMarketingExpense`	$8.31K	USD	Annual
Marketing and sales	`SellingAndMarketingExpense`	$9.62K	USD	Annual
Other expense, impairment of intangibles	`OtherExpenses`	-	USD	Annual
Other expense, impairment of intangibles	`OtherExpenses`	$2.00M	USD	Annual
Total costs and expenses	`CostsAndExpenses`	$5.59M	USD	Annual
Total costs and expenses	`CostsAndExpenses`	$1.53M	USD	Annual
Income (Loss) from operations	`OperatingIncomeLoss`	$-5.35M	USD	Annual
Income (Loss) from operations	`OperatingIncomeLoss`	$-409.43K	USD	Annual
Interest and dividend income	`OtherNonoperatingIncome`	$16.30K	USD	Annual
Interest and dividend income	`OtherNonoperatingIncome`	$16.09K	USD	Annual
Unrealized holding gain (loss) on investments	`UnrealizedGainLossOnInvestments`	$23.99K	USD	Annual
Unrealized holding gain (loss) on investments	`UnrealizedGainLossOnInvestments`	$14.57K	USD	Annual
Unrealized holding gain (loss) on asset sale	`GainsLossesOnSalesOfAssets`	$1.00K	USD	Annual
Unrealized holding gain (loss) on asset sale	`GainsLossesOnSalesOfAssets`	-	USD	Annual
Total other income	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$30.66K	USD	Annual
Total other income	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$41.28K	USD	Annual
Net income (loss)	`NetIncomeLoss`	$-378.76K	USD	Annual
Net income (loss)	`NetIncomeLoss`	$-5.31M	USD	Annual
Basic and diluted net income (loss) per share	`EarningsPerShareBasicAndDiluted`	$-0.04	USD	Annual
Basic and diluted net income (loss) per share	`EarningsPerShareBasicAndDiluted`	$-0.43	USD	Annual
Weighted average shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	10.79M	shares	Annual
Weighted average shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	12.43M	shares	Annual

Cash Flow Statement 50 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-378.76K	USD	Annual
Net loss	`NetIncomeLoss`	$-5.31M	USD	Annual
Depreciation	`Depreciation`	$2.10K	USD	Annual
Depreciation	`Depreciation`	$2.40K	USD	Annual
Amortization	`AmortizationOfIntangibleAssets`	$253.50K	USD	Annual
Amortization	`AmortizationOfIntangibleAssets`	$203.46K	USD	Annual
Equity based compensation	`ShareBasedCompensation`	$782.00K	USD	Annual
Equity based compensation	`ShareBasedCompensation`	$90.02K	USD	Annual
Other expense, impairment loss	`ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill`	-	USD	Annual
Other expense, impairment loss	`ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill`	$2.00M	USD	Annual
Unrealized gain on investments	`GainLossOnInvestments`	$-14.57K	USD	Annual
Unrealized gain on investments	`GainLossOnInvestments`	$-23.99K	USD	Annual
Realized (gain) loss on sale of investments, interest and dividends reinvested	`OtherNoncashExpense`	$-7.94K	USD	Annual
Realized (gain) loss on sale of investments, interest and dividends reinvested	`OtherNoncashExpense`	$-6.41K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$590.62K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$411.48K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$2.34K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$20.02K	USD	Annual
Prepaid expense and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-1.18K	USD	Annual
Prepaid expense and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$2.65K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.83K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$28.07K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$718.76K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$1.29K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-10.43K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$75.55K	USD	Annual
Deferred compensation	`DeferredCompensationArrangementWithIndividualCompensationExpense`	$106.94K	USD	Annual
Deferred compensation	`DeferredCompensationArrangementWithIndividualCompensationExpense`	$95.98K	USD	Annual
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$448.48K	USD	Annual
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-815.67K	USD	Annual
Purchase of equipment and patent costs	`PaymentsToAcquirePropertyPlantAndEquipment`	$95.50K	USD	Annual
Purchase of equipment and patent costs	`PaymentsToAcquirePropertyPlantAndEquipment`	$75.34K	USD	Annual
Contribution to deferred compensation trust	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition`	$-75.00K	USD	Annual
Contribution to deferred compensation trust	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition`	$-150.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-150.34K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-245.50K	USD	Annual
Exercise of Warrants and Options	`ProceedsFromStockOptionsExercised`	$194.44K	USD	Annual
Exercise of Warrants and Options	`ProceedsFromStockOptionsExercised`	$128.57K	USD	Annual
Issuance of Common Stock and warrants	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Issuance of Common Stock and warrants	`ProceedsFromIssuanceOfCommonStock`	$14.42M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$194.44K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$14.55M	USD	Annual
Increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$492.58K	USD	Annual
Increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$13.49M	USD	Annual
Cash and cash equivalents, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$283.27K	USD	Point-in-time
Cash and cash equivalents, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$775.86K	USD	Point-in-time
Cash and cash equivalents, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$14.26M	USD	Point-in-time
Cash and cash equivalents, end of year	`CashAndCashEquivalentsAtCarryingValue`	$283.27K	USD	Point-in-time
Cash and cash equivalents, end of year	`CashAndCashEquivalentsAtCarryingValue`	$775.86K	USD	Point-in-time
Cash and cash equivalents, end of year	`CashAndCashEquivalentsAtCarryingValue`	$14.26M	USD	Point-in-time

Stockholders Equity 17 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Amount	`StockholdersEquity`	$4.91M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$14.84M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$4.82M	USD	Point-in-time
Net Loss	`NetIncomeLoss`	$-378.76K	USD	Annual
Net Loss	`NetIncomeLoss`	$-5.31M	USD	Annual
Issuance of Common Stock and Warrants, Shares	`StockIssuedDuringPeriodSharesNewIssues`	-	shares	Annual
Issuance of Common Stock and Warrants, Amount	`StockIssuedDuringPeriodValueNewIssues`	-	USD	Annual
Issuance of Common Stock and Warrants, Amount	`StockIssuedDuringPeriodValueNewIssues`	$14.42M	USD	Annual
Exercise of Options and Warrants, Shares	`StockIssuedDuringPeriodSharesAcquisitions`	346,050.00	shares	Annual
Exercise of Options and Warrants, Shares	`StockIssuedDuringPeriodSharesAcquisitions`	128,572.00	shares	Annual
Exercise of Options and Warrants, Amount	`StockIssuedDuringPeriodValueAcquisitions`	$194.44K	USD	Annual
Exercise of Options and Warrants, Amount	`StockIssuedDuringPeriodValueAcquisitions`	$128.57K	USD	Annual
Equity Based Compensation	`ShareBasedCompensation`	$782.00K	USD	Annual
Equity Based Compensation	`ShareBasedCompensation`	$90.02K	USD	Annual
Ending Balance, Amount	`StockholdersEquity`	$4.91M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$14.84M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$4.82M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.